These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 26645827)
1. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow". Tabchi S; Ghosn M Target Oncol; 2016 Feb; 11(1):127-8. PubMed ID: 26645827 [No Abstract] [Full Text] [Related]
2. Comment on: "Regorafenib: Start Low and Go Slow". de la Fouchardière C Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250 [No Abstract] [Full Text] [Related]
3. Regorafenib: start low and go slow. Tabchi S; Ghosn M Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130 [No Abstract] [Full Text] [Related]
4. Regorafenib Also Can Cause Osteonecrosis of the Jaw. Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267 [No Abstract] [Full Text] [Related]
5. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Grothey A Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814 [No Abstract] [Full Text] [Related]
6. [Regorafenib approved in Metastatic Colorectal cancer]. André T; Dumont SN Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557 [TBL] [Abstract][Full Text] [Related]
7. [Regorafenib in patients with metastatic colorectal cancer: a review and an update]. Zaniboni A; Mansueto G Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548 [TBL] [Abstract][Full Text] [Related]
12. The role of regorafenib in metastatic colorectal cancer. Riechelmann R; Grothey A Lancet Oncol; 2015 Jun; 16(6):596-7. PubMed ID: 25981811 [No Abstract] [Full Text] [Related]
13. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose]. Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753 [TBL] [Abstract][Full Text] [Related]
14. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574 [TBL] [Abstract][Full Text] [Related]
15. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Giampieri R; Prete MD; Prochilo T; Puzzoni M; Pusceddu V; Pani F; Maccaroni E; Mascia R; Baleani MG; Meletani T; Berardi R; Lanzillo AM; Mariotti S; Zaniboni A; Cascinu S; Scartozzi M Sci Rep; 2017 Apr; 7():45703. PubMed ID: 28378839 [TBL] [Abstract][Full Text] [Related]
17. [Investigation of Administration Technique of Regorafenib in Our Center]. Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379 [TBL] [Abstract][Full Text] [Related]
18. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027 [TBL] [Abstract][Full Text] [Related]
19. Eruptive nevi and hair depigmentation related to regorafenib. Sibaud V; Munsch C; Lamant L Eur J Dermatol; 2015; 25(1):85-6. PubMed ID: 25514168 [No Abstract] [Full Text] [Related]